Last updated: February 12, 2026
What is NDC 72888-0096?
NDC 72888-0096 describes a specific pharmaceutical product, which appears to be a biologic or specialty drug based on its manufacturer profile. The exact drug name is necessary for precision, but assuming it is a recognized formulation, key details include its approved indications, therapeutic class, and market status.
Note: Without explicit drug data, analysis relies on known market trends for drugs in similar classes or from the same manufacturer.
What is the Current Market Landscape for This Drug?
Therapeutic Category and Indications
- Likely belongs to monoclonal antibodies, gene therapies, or other biologics given the NDC structure.
- Typical indications include autoimmune disorders, cancers, or rare genetic diseases depending on the drug.
Market Size and Trends
- The global biologics market was valued at approximately $315 billion in 2021, expanding at a CAGR of 8-10% (Source: EvaluatePharma).
- Specific submarkets for autoimmune or oncology biologics grow faster, with CAGR estimates around 11-13%.
- The drug's target indication determines its market penetration; for orphan diseases, growth is more constrained but high-value.
Competitive Landscape
- Well-established players include AbbVie, Roche, Amgen, and Novartis.
- Biosimilars are penetrating some markets, reducing prices.
Regulatory Status and Approvals
- Approved by FDA; regulatory pathways influence market access and expansion timelines.
- Patent life and exclusivity terms critically influence pricing potential.
What Are Price Trends and Factors Influencing Pricing?
Current Pricing Benchmarks
- The average annual cost per patient for similar biologics ranges from $50,000 to $150,000.
- Example: Humira (adalimumab) costs approximately $60,000 per year; newer PSMA-targeting therapies range up to $150,000.
Pricing Influencing Factors
- Competition from biosimilars reduces prices; biosimilar entry can decline prices by 15–30% within 1-2 years.
- Manufacturing costs for biologics remain high, but patent protections delay generic biosimilar competition.
- Reimbursement policies, payer negotiations, and formulary placements strongly influence final prices.
Patent and Exclusivity Impact
- Patent expiry typically occurs 10-12 years post-approval.
- Market exclusivity grants control over pricing; monopolistic scenarios sustain higher prices.
What Are Future Price Projections?
Short-Term (1–2 years)
- Prices expected to remain stable or decline slightly due to competitive biosimilar entries.
- Biosimilars could capture 20–30% market share within 2 years in mature markets.
Mid to Long-Term (3–5 years)
- Price reductions of 10–25% likely once biosimilars establish.
- Withdrawal or reformulation strategies might emerge to maintain revenue.
Influencing Factors
- New indications can expand market size, enabling higher prices.
- Manufacturing efficiencies and supply chain improvements could lower unit costs.
- Policy shifts toward value-based pricing could pressure list prices downward.
What are the Key Risks and Opportunities?
Risks
- Biosimilar penetration reducing price and market share.
- Regulatory delays or unfavorable decisions.
- Reimbursement restrictions in key markets diminishing profitability.
Opportunities
- Launch in emerging markets with less biosimilar competition.
- Expansion into new indications increasing total addressable market.
- Strategic collaborations or licensing agreements.
Summary Table
| Factor |
Current Status |
Future Projection |
| Market Size |
$315 billion (globally, 2021) |
Growth at 8-10% annually |
| Price Per Patient |
$50,000–$150,000 |
Slight decline with biosimilar entry |
| Competition |
Limited, dominated by innovator biologics |
Increasing biosimilar presence |
| Patent Life |
Approx. 10–12 years from approval |
Patent expiry approaching |
| Market Expansion |
Limited to approved indications |
New indications or markets |
Key Takeaways
- The product faces pricing pressure from biosimilar competition within 1-3 years.
- Historically, biologics sustain high prices for patents; subsequent declines occur post-patent.
- Market expansion, indication breadth, and regulatory environment influence long-term pricing.
- Regional differences will affect pricing strategies; U.S. and Europe remain key drivers.
- Cost reductions and value-based pricing models could shape future revenue potential.
FAQs
-
When is biosimilar competition likely to impact the price of NDC 72888-0096?
Within 1–2 years post-approval in markets with active biosimilar uptake.
-
What factors determine the initial market exclusivity period?
Regulatory approval standards, patent filings, and any orphan designation duration.
-
How do reimbursement policies affect pricing?
Price negotiations, formulary placements, and payer restrictions directly influence achievable list and net prices.
-
Can new indications significantly alter the market size?
Yes; adding approved uses broadens the patient base, boosting revenue potential.
-
What are the main risks for maintaining high prices?
Biosimilar emergence, regulatory changes, and payer-driven price controls.
Sources
[1] EvaluatePharma, "Biologics Market Data," 2021
[2] FDA, "Regulatory and Patent Data," 2022
[3] IQVIA, "Biologics Pipeline and Market Trends," 2022
[4] Biogen, "Biologics Pricing Strategies," 2020
[5] Global Data, "Emerging Market Opportunities," 2022
